Key statistics dashboard for Kalaris Therapeutics Inc (KLRS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Stock Data
| Price | $3.18 |
| Market Cap | $69M |
| Beta | 0.18 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.57 |
| Price / Book | 1.31 |
| P/S | 0.00 |
| P/FCF | -1.52 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 10.98 |
| Quick Ratio | 10.98 |
| Cash Ratio | 4.94 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.41% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -0.21 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.42 |
| Cash per share | 3.93 |
| FCF per share | -1.92 |
| Tangible Book Value per share | 2.42 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |